← Back to Clinical Trials
Recruiting Phase 2 NCT06122779
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Trial Parameters
Condition Heart Failure
Sponsor Bristol-Myers Squibb
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 208
Sex ALL
Min Age 40 Years
Max Age 85 Years
Start Date 2023-11-07
Completion 2026-07-03
Interventions
BMS-986435Placebo
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Eligibility Criteria
Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant. * Other protocol-defined Inclusion/Exclusion criteria apply.